22 May 2015

Plethora treatment wins NHS approval

15/04/2011 Ben Jaglom

Specialist pharmaceutical concern Plethora Solutions Holdings (PLE) says it has won approval for its vaginal dryness treatment Hyalofemme from the NHS for prescription.

The agreement means that doctors in the UK will now be able to write prescriptions for Hyalofemme for the first time for atrophic vaginitis, commonly referred to as vaginal dryness. Traditional treatments involve the use of hormonal creams containing estrogen, but such creams are often inappropriate for cancer patients, who often suffer vaginal dryness as a side effect of cancer treatment.

Chairman Bill Robinson remarks the decision by the NHS should 'increase the commercial value of our pipeline by exploiting products secured last year'. He adds that the release of Hyalofemme is an 'important treatment' for atrophic vaginitis.

Following the announcement analysts at house broker Daniel Stewart held their forecasts of a year-end loss of £1.3 million (2010: loss of £1.5 million) on revenue up £100,000 to £1.2 million. They have pencilled in a loss per share of 2.5p for 2011 and a further loss of 3.4p a share for 2012.

Shares in Plethora were up 0.25p this morning following the announcement to 7.5p, the price at which Growth Company Investor recommended them earlier this month. A good sign for the company's prospects, Hyalofemme will be prescribed both for those being treated for cancer and women going through the menopause. We therefore reiterate our speculative buy rating.

Tags: AIM market, Menopause, Pharma, Plethora Solutions Holdings, Urology Company, Vaginal dryness

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The Bahamas is one of the richest countries in the Caribbean

Bahamas sees second reading of Petroleum Bill 21/05/2015

Bahamas Petroleum (AIM:BPC) has noted that the Bahamian Parliament  is making progress on passing the Petroleum Bill.

Tags: Bahamas, Oil and gas

Stride joins AIM 21/05/2015

Online bingo operator Stride Gaming has joined AIM in an IPO that raised £11.2 million.

Tags: Gambling, IPOs

Optimal trading well 21/05/2015

Mobile payments specialist Optimal Payments (AIM:OPAY) issued a trading update.

Tags: Mobile payments

Secure Property expands holdings 21/05/2015

Eastern Europe-focused Secure Property Development & Investment has expanded its footprint in Romania and Bulgaria.

Tags: Eastern Europe, Property

Empyrean busy at Sugarloaf 21/05/2015

US oil play Empyrean Energy (AIM:EME) provided a production update on its Sugarloaf project.

Tags: Oil and gas, Texas

Escher's essential product 14/05/2015

Postal service specialist Escher Group (AIM:ESCH) has won a deal to supply its RiposteEssential software.

Tags: Contract win, Technology

More News